P-072Pembrolizumab versus investigator’s choice single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma that progressed after first-line therapy: Phase 3 KEYNOTE-181 study
Doi, Toshihiko, Bennouna, Jaafar, Shen, Lin, Enzinger, Peter, Wang, Ruixue, Dalal, Rita, Koshiji, Minori, Shah, ManishVolume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx261.071
Date:
June, 2017
File:
PDF, 124 KB
english, 2017